BCM
XFOR icon

Bayesian Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Bayesian Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,280
Closed -$25.7K – 1037
2024
Q3 		$25.7K Buy
+1,280
New +$26.7K ﹤0.01% 636
2024
Q1 		– Sell
-1,313
Closed -$33K – 1162
2023
Q4 		$33K Buy
+1,313
New +$31.9K ﹤0.01% 687

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's XFOR Position: Q4 2024 in Review

Bayesian Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 1,280 shares — an estimated $25.7K sold.

Bayesian Capital Management first reported a position in XFOR in Q4 2023 and held it in 2 quarters. The position peaked at $33K in Q4 2023. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Bayesian Capital Management reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 1,280 X4 Pharmaceuticals shares in Q4 2024, an estimated $25.7K.
  • Bayesian Capital Management first reported a position in X4 Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Bayesian Capital Management's X4 Pharmaceuticals position peaked at $33K in Q4 2023.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Bayesian Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.